All In Biotech

Drug Trial Radar · NCT05136664

Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects

A 2-Part, Single-Blind, Phase 3 Trial Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalaemia in Chinese Subjects (The Patiromer JADE Study)

Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 262 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

262

Actual

Start

Feb 10, 2022

Primary completion

Nov 18, 2025

Study completion Nov 18, 2025

Sponsor

Sponsor type
Industry
Collaborators
Tigermed Consulting Co., Ltd
First posted
Nov 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicentre, 2-part, single-blind, randomised, withdrawal, placebo-controlled study, that includes a 4-week patiromer treatment phase (Part A) followed by an 8-week randomised placebo-controlled withdrawal phase (Part B) and a 2-week follow-up period.

Conditions

  • Hyperkalemia
  • Renal Insufficiency, Chronic

Interventions

  • Patiromer Powder for Oral Suspension (Part A)Drug

    Participants initiate patiromer at an oral dose of 1 packet/day (8.4g/day as powder for suspension). The dose is adjusted ate the following visit based on local serum potassium (sK+) levels. The content of each packet should be mixed with water, apple or cranberry juice before administration.

  • Placebo (Part B)Drug

    Placebo is provided in packets, each containing 6 g of placebo as powder for suspension. Participants will take 1 packet per day, by mixing its content with water, apple or cranberry juice.

  • Patiromer Powder for Orals Suspension (Part B)Drug

    Participants will continue to receive the same number of packets established during Part A, but dose may be up- or down titrated depending on sK+ levels. The content of each packet should be mixed with water, apple or cranberry juice before administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Change from baseline in the serum potassium (sK+)Time frame: Week 4
  2. Part B: Change from Week 4 in sK+Time frame: The earlier of: Week 8 or the date when RAASi therapy is first decreased or discontinued

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Investigator Site 009

    Hefei, Anhui, China

  • Investigator Site 008

    Hefei, Anhui, China

  • Investigator Site 016

    Beijing, Beijing Municipality, China

  • Investigator Site 012

    Lanzhou, Gansu, China

  • Investigator Site 003

    Lanzhou, Gansu, China

  • Investigator Site 030

    Nanning, Guangxi, China

  • Investigator Site 024

    Nanyang, Henan, China

  • Investigator Site 010

    Wuhan, Hubei, China

  • Investigator Site 006

    Changsha, Hunan, China

  • Investigator Site 002

    Changzhou, Jiangsu, China

  • Investigator Site 019

    Nanjing, Jiangsu, China

  • Investigator Site 021

    Wuxi, Jiangsu, China

  • Investigator Site 005

    Xuzhou, Jiangsu, China

  • Investigator Site 013

    Zhenjiang, Jiangsu, China

  • Investigator Site 007

    Changchun, Jilin, China

  • Investigator Site 018

    Yinchuan, Ningxia, China

  • Investigator Site 028

    Shanghai, Pudong New Area, China

  • Investigator Site 015

    Shanghai, Shanghai Municipality, China

  • Investigator Site 022

    Taiyuan, Shanxi, China

  • Investigator Site 011

    Yuncheng, Shanxi, China

  • Investigator Site 004

    Chengdu, Sichuan, China

  • Investigator Site 014

    Tianjin, Tianjin Municipality, China

  • Investigator Site 027

    Zhuzhou, Tianyuan District, China

  • Investigator Site 023

    Ürümqi, Xinjiang, China

  • Investigator Site 001

    Hangzhou, Zhejiang, China

  • Investigator Site 020

    Hanzhou, Zhejiang, China

  • Investigator Site 026

    Jiaxing, Zhejiang, China

  • Investigator Site 025

    Jinhua, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.